ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (
Select Medical's Concentra Launches IPO for 22.5M Shares on NYSE
Select Medical Holdings Corporation ("Select Medical") (NYSE:SEM) today announced that Concentra Group Holdings Parent, Inc. ("Concentra"), a wholly owned subsidiary of Select Medical, has launched
Walmart Continues to Add More Restaurant Chains to Its Stores
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
ChromaDex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 129.89% HC Wainwright & Co. $6 → $6 Reiterates Buy → Buy 06/12/2024 129.89% Roth MKM $6 → $6
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $15 price target.
Inovio Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 30.1% HC Wainwright & Co. $15 → $15 Reiterates Neutral → Neutral 05/14/2024 73.46% Stephens &
Montrose Environmental Gr Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 44.15% Needham $54 → $54 Reiterates Buy → Buy 05/09/2024 44.15% Needham $54 → $54 Reiterates
Tenable Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 27.73% Baird → $55 Initiates Coverage On → Outperform 06/14/2024 43.99% Needham $62 → $62
Morgan Stanley Downgrades Staar Surgical to Underweight, Lowers Price Target to $37
Morgan Stanley analyst Patrick Wood downgrades Staar Surgical (NASDAQ:STAA) from Equal-Weight to Underweight and lowers the price target from $50 to $37.
MNC Capital Says It Has Absolutely No Intention Of Increasing Its $42 Per Share Vista Outdoor Offer; Questions Vista's Incomplete and Inaccurate Disclosures
MNC's letter included the following:"It is unfortunate that Vista has not engaged with us for almost two months, has failed to make disclosures that shareholders need to make an informed decision,
Staar Surgical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 — Needham Reiterates → Hold 06/11/2024 -0.84% BTIG → $46 Upgrades Neutral → Buy 05/08/2024 —
Rocket Lab USA Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 7.91% Morgan Stanley $8 → $6 Downgrades Overweight → Equal-Weight 07/01/2024 7.91% Cantor
Needham Reiterates Buy on Semtech, Maintains $50 Price Target
Needham analyst Quinn Bolton reiterates Semtech (NASDAQ:SMTC) with a Buy and maintains $50 price target.
Semtech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 39.66% Needham $50 → $50 Reiterates Buy → Buy 06/07/2024 39.66% Needham $50 → $50 Reiterates
Why Trump Media & TechnologyShares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Trump Media & Technology Group Corp. (NASDAQ:DJT) rose sharply in today's pre-market trading.The company's CEO Devin Nunes issued the following statement in response to the attempted
Ubs Group: Gold still has room for growth, but silver will perform better.
With the call for a rate cut growing louder, international gold prices have regained their upward momentum after a brief slump in the summer. UBS, which predicted that gold will rise to $2,700 next year, reiterated its bullish outlook on gold. However, UBS expects silver to outperform gold and have a greater potential to beat the market.
Goldman Sachs, BlackRock And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:Wall Street expects The Goldman Sachs Group, Inc. (NYSE:GS) to
US Stocks Close Higher, Dow Hits 40,000: Market Sentiment Remains In Greed Zone
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index remaining in the "Greed" zone on Friday.U.S. stocks closed higher on Friday, with the Dow